These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1526 related articles for article (PubMed ID: 29625053)

  • 21. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MaxCLK: discovery of cancer driver genes via maximal clique and information entropy of modules.
    Liu J; Ma F; Zhu Y; Zhang N; Kong L; Mi J; Cong H; Gao R; Wang M; Zhang Y
    Bioinformatics; 2023 Dec; 39(12):. PubMed ID: 38065693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer driver mutation prediction through Bayesian integration of multi-omic data.
    Wang Z; Ng KS; Chen T; Kim TB; Wang F; Shaw K; Scott KL; Meric-Bernstam F; Mills GB; Chen K
    PLoS One; 2018; 13(5):e0196939. PubMed ID: 29738578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations.
    Damodaran S; Miya J; Kautto E; Zhu E; Samorodnitsky E; Datta J; Reeser JW; Roychowdhury S
    J Mol Diagn; 2015 Sep; 17(5):554-9. PubMed ID: 26320871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-cancer landscape of
    Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
    Ding L; Bailey MH; Porta-Pardo E; Thorsson V; Colaprico A; Bertrand D; Gibbs DL; Weerasinghe A; Huang KL; Tokheim C; Cortés-Ciriano I; Jayasinghe R; Chen F; Yu L; Sun S; Olsen C; Kim J; Taylor AM; Cherniack AD; Akbani R; Suphavilai C; Nagarajan N; Stuart JM; Mills GB; Wyczalkowski MA; Vincent BG; Hutter CM; Zenklusen JC; Hoadley KA; Wendl MC; Shmulevich L; Lazar AJ; Wheeler DA; Getz G;
    Cell; 2018 Apr; 173(2):305-320.e10. PubMed ID: 29625049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency.
    Bokhari Y; Alhareeri A; Arodz T
    BMC Bioinformatics; 2020 Mar; 21(1):122. PubMed ID: 32293263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study.
    Kannan S; O'Connor GM; Bakker EY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What does PD-L1 positive or negative mean?
    Ribas A; Hu-Lieskovan S
    J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
    Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
    Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of druggable cancer driver genes amplified across TCGA datasets.
    Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
    PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
    Narayan S; Bader GD; Reimand J
    Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 77.